%0 Journal Article
%T Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
%A Fabien Calcagno
%A Thierry Nguyen
%A Erion Dobi
%A Cristian Villanueva
%A Elsa Curtit
%A Stefano Kim
%A Philippe Montcuquet
%A Fran ois Kleinclauss
%A Xavier Pivot and Antoine Thiery-Vuillemin
%J Clinical Medicine Insights: Oncology
%D 2012
%I 
%R 10.4137/CMO.S7256
%X Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men with castration-resistant prostate cancer (CRPC). Cabazitaxel (XRP6258, TXD258, and RPR116258A), a tubulin-binding taxane drug as potent as docetaxel in cell lines, was the first treatment able to prolong survival for metastatic CRPC in the post-docetaxel setting. This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed.
%U http://www.la-press.com/safety-and-efficacy-of-cabazitaxel-in-the-docetaxel-treated-patients-w-article-a3463